AI-generated personalized question lists to help people with lymphoma or multiple myeloma prepare for clinic visits.
Feasibility and Preliminary Efficacy of GPT-QPL: An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers
This study will test whether AI-generated personalized question lists help people with lymphoma or multiple myeloma ask better questions and get more useful information during outpatient appointments.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 20 Years to 99 Years |
| Sex | All |
| Sponsor | Washington University School of Medicine Academic / other |
| Drugs / interventions | Rituximab, chemotherapy, Cyclophosphamide, Doxorubicin, Prednisone |
| Locations | 1 site (St Louis, Missouri) |
| Trial ID | NCT07226934 on ClinicalTrials.gov |
What this trial studies
Patients with lymphoma or multiple myeloma who have an upcoming outpatient visit at Washington University will receive a standardized prompt tailored to their clinical characteristics and concerns. That prompt will be run through a HIPAA-compliant WashU ChatGPT to produce a personalized question prompt list (QPL) for their appointment. The trial will measure changes in patients' question-asking behavior, communicative self-efficacy, and self-reported amount and satisfaction with information obtained, and will collect user feedback on helpfulness and ease of use. Sub-analyses will examine patterns in questions generated by the AI.
Who should consider this trial
Good fit: Ideal candidates have a documented diagnosis of lymphoma (ICD-10 C81-C88) or multiple myeloma (ICD-10 C90.0-C90.02), a scheduled follow-up outpatient appointment at one of the participating WashU clinics within the next month, and are receiving infusion or injection-based systemic therapy given every 1–4 weeks.
Not a fit: Patients without an upcoming appointment at the listed WashU outpatient clinics, those not receiving infusion/injection-based disease-directed therapy (for example only receiving purely palliative regimens), or people treated outside the participating clinics are unlikely to benefit from this intervention.
Why it matters
Potential benefit: If successful, the intervention could help patients ask more relevant questions, feel more confident during clinic visits, and leave appointments better informed and more satisfied.
How similar studies have performed: Traditional question prompt lists have shown benefits for patient question-asking and information satisfaction in prior research, but using generative AI to create personalized QPLs is a novel approach with limited prior evidence.
Eligibility criteria
Show full inclusion / exclusion criteria
Eligibility Criteria as determined by Electronic Health Record (EHR) Screening: * Documented diagnosis of lymphoma, as defined by ICD-10 codes C81-C88 or multiple myeloma, as defined by ICD codes C90.0-C90.02 * Has a scheduled follow-up appointment at a participating outpatient oncology clinic within the next month. Participating clinics include: * Dr. David Russler-Germain: Outpatient Lymphoma Clinic * Dr. Michael Slade: Outpatient Multiple Myeloma Clinic * Undergoing infusion or injection-based systemic therapy intended to cure or manage the disease, as opposed to regimens delivered solely for palliative purposes, at a frequency of once every 1-4 weeks. * For eligible patients with lymphoma, this includes, but is not limited to, commonly prescribed treatment combinations such as R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin/Hydroxydaunorubicin, Vincristine, and Prednisone) for Non-Hodgkin Lymphoma, or ABVD (Adriamycin/Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine) for Hodgkin Lymphoma-both regimens that are frequently administered every three weeks * For patients with multiple myeloma, eligibility will include patients in the "induction" phase of chemotherapy treatment, which frequently requires patients to come in for outpatient appointments once every four weeks as well as patients in a maintenance phase of treatment that otherwise requires them to attend outpatient appointments at a frequency of every one to four weeks * Between age 20-99 at enrollment (Patients aged 18-19 and older than 99 will be excluded so that the study team is able to elicit questions from WashU ChatGPT using a standardized prompt that describes the patient's age only as specifically as a 10-year decade range (i.e., "I am a patient in my 20's, 30's, 40's, etc.). * Able to consent to medical care independently (does not have a legally authorized representative or documented diagnosis of cognitive impairment) Eligibility Criteria as determined by subsequent recruitment phone call or In-person approach after a clinic appointment: * Does not have visual impairments or English literacy limitations that would interfere with ability to engage in an intervention that requires being able to read material on an electronic device and on paper and communicate aloud during appointments with health care providers, based on patient self-report * Able to use email (consent form will be distributed electronically through DocuSign and associated emails), based on successful completion of electronic informed consent
Where this trial is running
St Louis, Missouri
- Washington University School of Medicine — St Louis, Missouri, United States (Recruiting)
Study contacts
- Principal investigator: Jessica Hahne, MA, MPH — Washington University School of Medicine
- Study coordinator: Jessica Hahne, MA, MPH
- Email: hahne.j@wustl.edu
- Phone: 314-935-6173
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.